Dermata Therapeutics, Inc. (DRMA) Research
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
Market snapshot
- Symbol
- DRMA
- Price
- $1.17
- Day change
- -12.03%
- Market cap
- $797.4K
- P/E ratio
- -0.64x
- 52-week range
- 1.1-8
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $6.00
Peer companies
Recent insider activity
- Scott Kathleen D. — S-Sale (11 shares) on 2026-06-16
- Bedoya-Toro Munera Maria E — P-Purchase (1000 shares) on 2026-02-17
- PROEHL GERALD T — A-Award (37500 shares) on 2026-01-02
- HALE DAVID F — A-Award (2500 shares) on 2026-01-02
- WIERENGA WENDELL — A-Award (2500 shares) on 2026-01-02
Open Dermata Therapeutics, Inc. (DRMA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.